Arrowhead Pharmaceuticals, Inc.
Compositions and Methods for Inhibiting Gene Expression of Alpha-1 AntiTrypsin
Last updated:
Abstract:
The invention relates to a RNA interference triggers for inhibiting the expression of an AAT gene through the mechanism of RNA interference. The invention also relates to a pharmaceutical composition comprising the AAT RNAi trigger together with an excipient capable of improving delivery of the RNAi trigger to a liver cell in vivo. Delivery of the AAT RNAi trigger to liver cells in vivo provides for inhibition of AAT gene expression and treatment of alpha 1-antitrypsin deficiency and associated diseases.
Status:
Application
Type:
Utility
Filling date:
31 May 2019
Issue date:
19 Sep 2019